Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.62 |
| ▸ | TK1 | P04183 | 2/20 | 0.50 |
| ▸ | TK2 | O00142 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13301589 | 1.00 | DUT (0.62) | DUTTK1TK2SLC28A1SLC28A2 | |
| SCHEMBL25025058 | 1.00 | DUT (0.62) | DUTTK1TK2SLC28A1SLC28A2 | |
| SCHEMBL14106710 | 1.00 | DUT (0.62) | DUTTK1TK2SLC28A1SLC28A2 | |
| SCHEMBL13944250 | 1.00 | DUT (0.62) | DUTTK1TK2SLC28A1SLC28A2 | |
| Deoxyuridine SCHEMBL114598 | 0.88 | DUT (0.64) | DUTTK1TK2SLC28A1SLC28A2 | |
| Deoxyuridine SCHEMBL28844 | 0.88 | DUT (0.64) | DUTTK1TK2SLC28A1SLC28A2 | |
| Deoxyuridine SCHEMBL9219261 | 0.88 | DUT (0.64) | DUTTK1TK2SLC28A1SLC28A2 | |
| Deoxyuridine SCHEMBL4847460 | 0.88 | DUT (0.64) | DUTTK1TK2SLC28A1SLC28A2 | |
| Deoxyuridine SCHEMBL24512520 | 0.88 | DUT (0.64) | DUTTK1TK2SLC28A1SLC28A2 | |
| Deoxyuridine SCHEMBL889540 | 0.88 | DUT (0.64) | DUTTK1TK2SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7795238-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100152126-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | INDENIX PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7304043-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | DUT 2/4885TK1 34/4885TK2 32/4885 |
| US-20100152126-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | DUT 2/4885TK1 34/4885TK2 32/4885 |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | DUT 2/4885TK1 34/4885TK2 32/4885 |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | ATIC, SLC35B2, AASDHPPT | DUT 7/4885TK1 60/4885TK2 56/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | DUT 2/4885TK1 34/4885TK2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.